Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, ottobre 27
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Legend Biotech Corp
LEGN
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$20.39
1.12
5.81%
Ult. Agg.: Oct 26, 4:00 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Legend Biotech Financials
Legend Biotech (LEGN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Legend Biotech Q2 Adj. EPS $0.16 Beats $0.07 Estimate, Sales $387.500M Beat $355.772M Estimate
Legend Biotech (NASDAQ:LEGN) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.07 by 100 percent. This is a 147.06 percent increase over losses of $(0.34) per share from the
Benzinga Newsdesk
These Analysts Revise Their Forecasts On Legend Biotech After Q1 Results
Legend Biotech (LEGN) reported Q1 losses of 3 cents per share and sales of $305.1 million, missing estimates. Stock rose 1.3% to $28.63. Analysts maintained ratings and adjusted price targets.
Avi Kapoor
Earnings Scheduled For May 12, 2026
Benzinga Insights
PRO
Legend Biotech Q1 Adj. EPS $(0.03) Misses $(0.02) Estimate, Sales $305.100M Miss $307.035M Estimate
Legend Biotech (NASDAQ:LEGN) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 57.14 percent increase over losses of $(0.07) per share from the
Benzinga Newsdesk
Earnings Scheduled For March 10, 2026
Benzinga Insights
Legend Biotech Q4 Earnings Summary & Key Takeaways
Benzinga Insights
